Issue Information ‐ Meeting Notices
31 January 2019
31 January 2019
31 January 2019
Shalimar, Mohammed Faisal Sheikh, Rajeshwar P. Mookerjee, Banwari Agarwal, Subrat Kumar Acharya, Rajiv Jalan – 31 January 2019 – Ammonia is thought to be central to the pathogenesis of hepatic encephalopathy (HE), but its prognostic role in patients with cirrhosis and acute decompensation is unknown. The aims of this study were to determine the relationship between ammonia levels and severity of HE and its association with organ dysfunction and short‐term mortality. We identified 498 patients from two institutions as part of prospective observational studies in patients with cirrhosis.
Heng Wu, Jonathan M. Ploeger, Sushama Kamarajugadda, Douglas G. Mashek, Mara T. Mashek, Juan C. Manivel, Laurie L. Shekels, Jessica L. Lapiro, Jeffrey H. Albrecht – 30 January 2019 – During normal proliferation, hepatocytes accumulate triglycerides (TGs) in lipid droplets (LDs), but the underlying mechanisms and functional significance of this steatosis are unknown. In the current study, we examined the coordinated regulation of cell cycle progression and LD accumulation. As previously shown, hepatocytes develop increased LD content after mitogen stimulation.
29 January 2019
29 January 2019
29 January 2019
Nicolas Weiss, Dominique Thabut – 29 January 2019 – Orthotopic liver transplantation (LT) remains the only way to definitively cure patients with the most severe liver diseases. Because the survival rate is now fairly high, important questions about neurological sequelae or quality of life after LT have emerged. Indeed, LT represents a peculiar situation because up to 30% of patients present with neurological symptoms after LT compared with only 4% after cardiac transplant and 0.5% after renal transplant.
François Durand, Corinne Antoine, Olivier Soubrane – 29 January 2019 – In France, the main indications for liver transplantation are hepatocellular carcinoma (HCC) and alcoholic cirrhosis. The number of candidates for decompensated hepatitis C virus–related cirrhosis has markedly decreased since the advent of direct‐acting antiviral agents. Nonalcoholic steatohepatitis represents a lower proportion of candidates as compared with the United States.
A. Jay Freeman, Zachary M. Sellers, George Mazariegos, Andrea Kelly, Lisa Saiman, George Mallory, Simon C. Ling, Michael R. Narkewicz, Daniel H. Leung – 29 January 2019 – Approximately 5%‐10% of patients with cystic fibrosis (CF) will develop advanced liver disease with portal hypertension, representing the third leading cause of death among patients with CF. Cystic fibrosis with advanced liver disease and portal hypertension (CFLD) represents the most significant risk to patient mortality, second only to pulmonary or lung transplant complications in patients with CF.